Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy.
We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.
Background Type 2 diabetes mellitus is a public health concern, and projections of its future effect are alarming. According to the World Health Organization, diabetes affects more than 170 million people worldwide, and this number will rise to 370 million by 2030 [1]. About one third of those affected will eventually have progressive deterioration of renal function [2, 3]. The first clinical sign of renal dysfunction in patients with diabetes is generally microalbuminuria (a sign of endothelial dysfunction that is not necessarily confined to the kidney)[4], which develops in 2 to 5 percent of patients per year [5,6]. In type 2 diabetes, unlike type 1 diabetes [7], microalbuminuria is seldom reversible [8], but, instead, progresses to overt proteinuria in 20 to 40 percent of patients.[9,10]. In 10 to 50 percent of patients with proteinuria, chronic kidney disease develops that ultimately requires dialysis or transplantation [11,12,13]. Forty to 50 percent of patients with type 2 diabetes who have microalbuminuria eventually die of cardiovascular disease [14,15]; this is three times as high a rate of death from cardiac causes as among patients who have diabetes but have no evidence of renal disease [6].
In patients with diabetes and renal disease, lowering blood pressure and the levels of urinary albumin is effective in reducing the risk of end-stage renal disease as well as that of myocardial infarction, heart failure, and stroke [16]. Angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II antagonists appear to be the most effective renoprotective and antihypertensive agents [11, 12, 17-21] . Treatment with the ACE inhibitor enalapril over a period of six years decreased the incidence of microalbuminuria in patients with type 2 diabetes who were normotensive and not obese [22].
Preventing (or delaying) the development of microalbuminuria is a key treatment goal for renoprotection [23] and, possibly, for cardioprotection [4]. Recent clinical trials suggested that inhibition of the renin-angiotensin system may actually prevent nephropathy. The post hoc analyses of the reduction in hypertension in the Heart Outcomes Prevention Evaluation study [18] and in the Losartan Intervention for Endpoint study [24] found a lower incidence of overt nephropathy in subjects with type 2 diabetes who received therapy that inhibited the renin-angiotensin system than in controls.
Recent BENEDICT study indicates that treatment with trandolapril with or without verapamil significantly reduces the incidence of microalbuminuria in patients with type 2 diabetes and normal urinary albumin excretion, as compared with placebo [25]. Trandolapril alone also appeared to decrease the incidence of microalbuminuria, whereas verapamil had no effect. Thiseffect of trandolapril plus verapamil and trandolapril alone in preventing microalbuminuria exceeded expectations based on changes in blood pressure alone.
Unfortunately, even with the appropriate use of available therapy, diabetic nephropathy still remains the leading cause of ESRD [2]. More effective strategies are needed in order to retard the progression of diabetic nephropathy and to reduce cardiovascular mortality in diabetic population.
Thiazolidinediones (TZDs) represent a class of compounds currently used for the treatment of type 2 DM that exert their hypoglycemic properties through reduction of IR [26]. These agents act by stimulating a certain type of nuclear receptor, called peroxisome proliferator-activated receptor gamma (PPAR ). Such receptors are abundant in adipose tissue cells, but they are also present in various other cell types, such as vascular smooth muscle cells, macrophages, vascular endothelial cells, colon epithelial cells, as well as renal glomerular and tubular cells. Through transcriptional regulation of various genes, PPAR receptors play an important role in adipocyte differentiation and lipid and carbohydrate metabolism [26]. Apart from improving glycemic control in patients with type 2 DM, several lines of evidence support the notion that TZDs have beneficial effects on other components of the metabolic syndrome, such as blood pressure (BP) lowering, triglyceride reduction, high-density lipoprotein-cholesterol elevation, redistribution of body fat away from the central compartment, decrease of C-reactive protein and plasminogen activator inhibitor -1 (PAI-1) levels, and others [26].
Additionally, several animal studies demonstrate that TZDs also reduce urine albumin or protein excretion and protect against injury to the kidney [27]. Moreover, experimental studies exposed numerous actions of TZDs in the kidney that could explain a possible renoprotective effect [27-30]. Our recent study on diabetic rats showed that rosiglitazone exerts its anti-inflammatory renoprotective effect by inhibition of mesangial cells proliferation, downregulation of apoptosis and blunting responsiveness to angiotensin-2 [31].
Human study also report significant reductions in UAE among patients with type 2 diabetes by rosiglitazone [32].
Another human study was part of a cardiac safety study where rosiglitazone 4 mg b.i.d. was compared to glyburide in 121 patients for 52 weeks [32]. After 28 weeks of treatment, both groups had significant reductions in ACR of about 30%, but after 52 weeks only rosiglitazone group continued to demonstrate a significant ACR reduction. This finding suggests that duration of follow-up is an important variable in assessing the effect of TZDs [32].
Overall, the above data clearly show that TZD treatment can reduce UAE. However, it should be emphasized that currently there are no trials that examine the effects of TZDs on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy [33]. Such studies are needed in order to provide the best evidence for a renoprotective effect of TZDs.
Based on this data, we decided to study the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy.
Methods. Study population. The study is planned as retrospective cohort study using automated clinical data of Central Region Clalit Health Survices from 1999 until 2007.
Inclusion criteria: 1. Diagnosis of Diabetes Mellitus Type II; 2. Treatment With Oral hypoglycemics; 3. Availability of Baseline and follow up clinical data Exclusion criteria: 1. Insulin Therapy at baseline; 2. Malignancy Patients will be divided into 2 groups: rosiglitazone-treated group and non-treated with rosiglitazone ( control) group.
Baseline Data ( separately for two groups). Number of patients. Gender Race/etnicity Age Weight, BMI Duration of DM Diabetic microangiopathy: retinopathy, neuropathy, nephropathy Medications for DM Creatinine Microalbumin Proteinuria HbA1c% Hb Ca, P, PTH Albumin Hypertension: BP Cholesterol, LDL, TG Smoking: current, previous Alcohol consumption Comorbidites: HTN, CAD, CHF, PVD, Hypercholesterolemia, CVA/TIA Drugs: ACEi, ARBs, CCB, beta-blockers, statines, antiplatlate Use of nephrotoxic medications: NSAIDs
Follow up data Duration of rosiglitasone therapy/follow up Use of contrast media during study
Every year data:
Creatinine eGFR Microalbumin Proteinuria HbA1C% Start of insulin therapy
Events:
Hospitalisation (cause) Death (cause) ESRD/Dialysis Reported CHF MI CVA Angiography PVD Amputation References
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Rosiglitasone (retrospective observation) | Drug |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Leonid S Feldman | Contact | +972-8-9779383 | 9383 | leonidf@asaf.health.gov.il |
| Name | Affiliation | Role |
|---|---|---|
| Leonid S Feldman | Nephrology Division, Assaf Harofeh Medical Center, Zerifin, | Principal Investigator |
| Leonid S Feldman | Assaf-Harofeh Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clalit Health Cervices, Central District | Ẕerifin | 70300 | Israel |
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003928 | Diabetic Nephropathies |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D048909 | Diabetes Complications |